CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Nimbus Discovery LLC, a biotechnology company discovering novel medicines against exciting but previously inaccessible disease targets, today announced that Daniel S. Lynch has been appointed to the company’s Board of Directors as Executive Chairman. Dan will succeed Bruce Booth, D. Phil., Partner at Atlas Venture and Co-Founder of Nimbus, who will remain on the Board.
“One of Dan’s many strengths is his ability to drive young companies to achieve their goals. In particular, his proven track record in creating value through partnerships will be important as we secure a series of program-focused transactions”, said Bruce Booth. “His expertise in strategy and executive management will provide a valuable resource to the Nimbus team and Board,” Booth added.
Previously, Dan was Executive Chairman at Avila (acquired by Celgene in 2012) and Stromedix (acquired by Biogen Idec in 2012). Dan has more than 25 years experience serving in management positions in the biotechnology and pharmaceutical industries. Dan was CEO and CFO at ImClone Systems, which he led through a significant turnaround, helping to restore the company’s reputation and to secure FDA approval of ERBITUX® (cetuximab), a novel cancer treatment. Earlier, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure.
“Nimbus Discovery is successfully developing drugs for sought-after targets where traditional chemistry approaches have failed,” said Dan Lynch. “Nimbus has established a radically new approach to drug discovery that has the potential to transform the entire industry pipeline with innovative medicines.”
Nimbus Discovery, a biotechnology company, harnesses cutting-edge computational technologies to uncover breakthroughs in small molecule pharmacology. We focus on medically important and highly sought-after disease targets that have proven inaccessible to traditional industry approaches. Our robust pre-clinical pipeline includes novel agents for the treatment of cancer, metabolic disease and inflammation. Nimbus is organized as a constellation of small, nimble teams of experienced drug-hunters deployed across program-focused subsidiary companies. Each team is freed from conventional barriers to scientific success, chartered to create solutions, and geared for program asset deals with leading pharmaceutical companies. Founded in 2009, Nimbus partnered with Schrödinger to invent and apply a physics-based approach that establishes a new standard for rational drug design. Nimbus is backed by world-class life science investors, including Atlas Venture, SR One, Lilly Ventures and Gates Ventures. For more information please visit www.nimbusdiscovery.com.
Source: Nimbus Discovery